Pub Date : 2025-03-01DOI: 10.1016/j.cardfail.2024.10.001
ALEXANDER G. HAJDUCZOK , ELENA M. DONALD , JENNIFER MANING , QUENTIN YOUMANS , NOSHEEN REZA
{"title":"Can't Rain on Our Parade: Highlights from the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024","authors":"ALEXANDER G. HAJDUCZOK , ELENA M. DONALD , JENNIFER MANING , QUENTIN YOUMANS , NOSHEEN REZA","doi":"10.1016/j.cardfail.2024.10.001","DOIUrl":"10.1016/j.cardfail.2024.10.001","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 3","pages":"Pages 574-578"},"PeriodicalIF":6.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.cardfail.2025.01.014
YANPING LI PhD , XUAN-MAI T. NGUYEN MD PhD , TIMOTHY TREU MPH , DONG D. WANG ScD , YUK-LAM HO MPH , SERENA C. HOUGHTON PhD , BRIAN CHAREST MPH , RUIFENG LI PhD , DANIEL POSNER PhD , MARY PYATT MPH , MARYAM RAHAFROOZ PhD , SRIDHARAN RAGHAVAN MD , DAVID R. GAGNON PhD , STACEY B. WHITBOURNE PhD , JOHN MICHAEL GAZIANO MD , LUC DJOUSSE MD , JACOB JOSEPH MD , PETER W.F. WILSON MD , KELLY CHO PhD , Million Veteran Program
{"title":"Association of Life's Essential 8 With Incident Heart Failure and Its Prognosis","authors":"YANPING LI PhD , XUAN-MAI T. NGUYEN MD PhD , TIMOTHY TREU MPH , DONG D. WANG ScD , YUK-LAM HO MPH , SERENA C. HOUGHTON PhD , BRIAN CHAREST MPH , RUIFENG LI PhD , DANIEL POSNER PhD , MARY PYATT MPH , MARYAM RAHAFROOZ PhD , SRIDHARAN RAGHAVAN MD , DAVID R. GAGNON PhD , STACEY B. WHITBOURNE PhD , JOHN MICHAEL GAZIANO MD , LUC DJOUSSE MD , JACOB JOSEPH MD , PETER W.F. WILSON MD , KELLY CHO PhD , Million Veteran Program","doi":"10.1016/j.cardfail.2025.01.014","DOIUrl":"10.1016/j.cardfail.2025.01.014","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 3","pages":"Pages 598-602"},"PeriodicalIF":6.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Critical Time for Tafamidis in the Real World – Will the Data Support its First Mover Advantage?","authors":"Paloma Remior-Perez MD , Sumeet Singh Mitter MD, MSc","doi":"10.1016/j.cardfail.2025.01.003","DOIUrl":"10.1016/j.cardfail.2025.01.003","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 3","pages":"Pages 534-537"},"PeriodicalIF":6.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.cardfail.2024.06.005
MARTINE WEBB MD , NICHOLAS K. BROWNELL MD , SONYA GABRIELIAN MD , GREGG C. FONAROW MD , BOBACK ZIAEIAN MD, PhD
<div><h3>Background</h3><div>How housing insecurity might affect patients with heart failure (HF) is not well characterized. Housing insecurity increases risks related to both communicable and noncommunicable diseases. For patients with HF, housing insecurity is likely to increase the risk for worse outcomes and rehospitalizations.</div></div><div><h3>Methods and Results</h3><div>We analyzed hospitalizations due to HF in the United States by using the 2020 National Inpatient Sample and Nationwide Readmissions Database to evaluate the impacts of housing insecurity on HF outcomes and hospital use. Individuals were identified as having housing insecurity by using diagnostic International Classification of Disease (ICD)-10 codes. Demographics and comorbidities were compared between patients with HF with and without housing insecurity. An adjusted logistic regression was performed to evaluate the relationships between housing insecurity and socioeconomic status on in-hospital mortality. Using a Cox proportional hazards model, patients with HF and without housing insecurity were evaluated for the risk of all-cause and HF-specific readmissions over time. Of the 1,003,270 hospitalizations for HF in the U.S. in 2020, 16,150 were identified as having housing insecurity (1.6%), and 987,120 were identified as having no housing insecurity (98.4%). The median age of patients with housing insecurity who were hospitalized for HF was 57, as compared to 73 in the population with no housing insecurity. A higher proportion of patients in the housing-insecurity group were Black (35% vs 20.1%) or Hispanic (11.1% vs 7.3%). Patients with housing insecurity were more likely to carry a diagnosis of alcohol-use disorder (15.2% vs 3.3%) or substance-use disorder (70.2% vs 17.8%) but were less likely to use tobacco (18.3% vs 28.7%). Patients with housing insecurity were over 4.5 times more likely to have Medicaid (52.4% vs 11.3%). Median length of stay did not differ between patients with housing insecurity vs those without it. Patients with housing insecurity were more likely to discharge against medical advice (11.4% vs 2.03%). After adjusting for patients’ characteristics, housing insecurity was associated with lower in-hospital mortality rates (OR 0.60, 95% CI 0.39–0.92). Housing insecurity was associated with a higher risk of all-cause readmissions at 180 days (HR 1.13, 95% CI 1.12–1.14). However, there was no significant difference in the risk of HF-specific readmissions at 180 days (HR 1.07, 95% CI 0.998–1.14)</div></div><div><h3>Conclusions</h3><div>Patients with HF and housing insecurity have distinct demographic characteristics. They are also more likely to be readmitted after their initial hospitalization when compared to those without housing insecurity. Identifying and addressing specific comorbid conditions for patients with housing insecurity who are hospitalized for HF may allow clinicians to provide more focused care, with the goal of preventing morbidity, m
{"title":"Examining Heart Failure Outcomes Amid Housing Insecurity","authors":"MARTINE WEBB MD , NICHOLAS K. BROWNELL MD , SONYA GABRIELIAN MD , GREGG C. FONAROW MD , BOBACK ZIAEIAN MD, PhD","doi":"10.1016/j.cardfail.2024.06.005","DOIUrl":"10.1016/j.cardfail.2024.06.005","url":null,"abstract":"<div><h3>Background</h3><div>How housing insecurity might affect patients with heart failure (HF) is not well characterized. Housing insecurity increases risks related to both communicable and noncommunicable diseases. For patients with HF, housing insecurity is likely to increase the risk for worse outcomes and rehospitalizations.</div></div><div><h3>Methods and Results</h3><div>We analyzed hospitalizations due to HF in the United States by using the 2020 National Inpatient Sample and Nationwide Readmissions Database to evaluate the impacts of housing insecurity on HF outcomes and hospital use. Individuals were identified as having housing insecurity by using diagnostic International Classification of Disease (ICD)-10 codes. Demographics and comorbidities were compared between patients with HF with and without housing insecurity. An adjusted logistic regression was performed to evaluate the relationships between housing insecurity and socioeconomic status on in-hospital mortality. Using a Cox proportional hazards model, patients with HF and without housing insecurity were evaluated for the risk of all-cause and HF-specific readmissions over time. Of the 1,003,270 hospitalizations for HF in the U.S. in 2020, 16,150 were identified as having housing insecurity (1.6%), and 987,120 were identified as having no housing insecurity (98.4%). The median age of patients with housing insecurity who were hospitalized for HF was 57, as compared to 73 in the population with no housing insecurity. A higher proportion of patients in the housing-insecurity group were Black (35% vs 20.1%) or Hispanic (11.1% vs 7.3%). Patients with housing insecurity were more likely to carry a diagnosis of alcohol-use disorder (15.2% vs 3.3%) or substance-use disorder (70.2% vs 17.8%) but were less likely to use tobacco (18.3% vs 28.7%). Patients with housing insecurity were over 4.5 times more likely to have Medicaid (52.4% vs 11.3%). Median length of stay did not differ between patients with housing insecurity vs those without it. Patients with housing insecurity were more likely to discharge against medical advice (11.4% vs 2.03%). After adjusting for patients’ characteristics, housing insecurity was associated with lower in-hospital mortality rates (OR 0.60, 95% CI 0.39–0.92). Housing insecurity was associated with a higher risk of all-cause readmissions at 180 days (HR 1.13, 95% CI 1.12–1.14). However, there was no significant difference in the risk of HF-specific readmissions at 180 days (HR 1.07, 95% CI 0.998–1.14)</div></div><div><h3>Conclusions</h3><div>Patients with HF and housing insecurity have distinct demographic characteristics. They are also more likely to be readmitted after their initial hospitalization when compared to those without housing insecurity. Identifying and addressing specific comorbid conditions for patients with housing insecurity who are hospitalized for HF may allow clinicians to provide more focused care, with the goal of preventing morbidity, m","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 3","pages":"Pages 511-520"},"PeriodicalIF":6.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141544896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.cardfail.2024.08.054
ALEXANDRA STEVERSON MD, MPH , JAMIE CALMA BA , STEPHANIE HSIAO MD , KARIM SALLAM MD , ANUBODH S. VARSHNEY MD , JESSICA R. GOLBUS MD, MS , PAUL A. HEIDENREICH MD, MS , ALEXANDER T. SANDHU MD, MS
{"title":"Validating the Association Between Composite Metrics of Guideline-Directed Medical Therapy and Clinical Outcomes for Patients With Heart Failure With Reduced Ejection Fraction","authors":"ALEXANDRA STEVERSON MD, MPH , JAMIE CALMA BA , STEPHANIE HSIAO MD , KARIM SALLAM MD , ANUBODH S. VARSHNEY MD , JESSICA R. GOLBUS MD, MS , PAUL A. HEIDENREICH MD, MS , ALEXANDER T. SANDHU MD, MS","doi":"10.1016/j.cardfail.2024.08.054","DOIUrl":"10.1016/j.cardfail.2024.08.054","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 3","pages":"Pages 588-591"},"PeriodicalIF":6.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.cardfail.2025.01.004
SHELDON E. LITWIN MD
{"title":"Balancing Fat Loss and Muscle Loss in the Quest to Reduce Obesity in Patients with Heart Failure","authors":"SHELDON E. LITWIN MD","doi":"10.1016/j.cardfail.2025.01.004","DOIUrl":"10.1016/j.cardfail.2025.01.004","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 3","pages":"Pages 508-510"},"PeriodicalIF":6.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143038872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.cardfail.2025.02.007
Anuradha Lala MD , Robert J. Mentz MD
{"title":"Our Second Mountain: Refining the Vision of JCF","authors":"Anuradha Lala MD , Robert J. Mentz MD","doi":"10.1016/j.cardfail.2025.02.007","DOIUrl":"10.1016/j.cardfail.2025.02.007","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 3","pages":"Pages 495-496"},"PeriodicalIF":6.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.cardfail.2024.06.003
PABLO GARCIA-PAVIA MD, PhD , ARNT V. KRISTEN MD , BRIAN DRACHMAN MD , MARTIN CARLSSON MS , LESLIE AMASS PhD , FRANCA STEDILE ANGELI MD, PhD , MATHEW S. MAURER MD , THAOS investigators
Background
In the pivotal Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis significantly reduced mortality rates, leading to its approval in many countries for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Real-world evidence on survival in patients with ATTR-CM following tafamidis treatment has not been extensively reported.
Methods and Results
The Transthyretin Amyloidosis Outcomes Survey (THAOS) was a longitudinal, observational, phase 4 study of patients with transthyretin amyloidosis and asymptomatic participants carrying pathogenic transthyretin variants. Patients from THAOS with a predominantly cardiac phenotype at enrollment were included, and survival was analyzed according to tafamidis treatment status (treated or untreated). Results are based on the completed THAOS dataset. In tafamidis-treated (n = 587) and tafamidis-untreated (n = 854) patients, respectively, median age at enrollment was 77.7 and 76.4 years, 91.8% and 90.0% were male, and 91.8% and 83.8% had wild-type disease. Survival rates (95% CI) at 30 and 42 months, respectively, were 84.4% (80.5–87.7) and 76.8% (70.9–81.7) in tafamidis-treated patients, and 70.0% (66.4-73.2) and 59.3% (55.2-63.0) in tafamidis-untreated patients. Survival rates in genotype subgroups (wild-type and variant) were similar to those of the overall cohort. Survival rates were better in a contemporary cohort, as reflected by a sensitivity analysis performed in patients enrolled after vs before 2019. No new safety signals were identified.
Conclusions
In this real-world cohort of patients with ATTR-CM, survival rates were higher than in ATTR-ACT and consistent with more recent reports, suggesting early diagnosis and treatment with tafamidis has improved life expectancy in ATTR-CM. These results provide further evidence supporting tafamidis’ safety and effectiveness.
{"title":"Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)","authors":"PABLO GARCIA-PAVIA MD, PhD , ARNT V. KRISTEN MD , BRIAN DRACHMAN MD , MARTIN CARLSSON MS , LESLIE AMASS PhD , FRANCA STEDILE ANGELI MD, PhD , MATHEW S. MAURER MD , THAOS investigators","doi":"10.1016/j.cardfail.2024.06.003","DOIUrl":"10.1016/j.cardfail.2024.06.003","url":null,"abstract":"<div><h3>Background</h3><div>In the pivotal Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis significantly reduced mortality rates, leading to its approval in many countries for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Real-world evidence on survival in patients with ATTR-CM following tafamidis treatment has not been extensively reported.</div></div><div><h3>Methods and Results</h3><div>The Transthyretin Amyloidosis Outcomes Survey (THAOS) was a longitudinal, observational, phase 4 study of patients with transthyretin amyloidosis and asymptomatic participants carrying pathogenic transthyretin variants. Patients from THAOS with a predominantly cardiac phenotype at enrollment were included, and survival was analyzed according to tafamidis treatment status (treated or untreated). Results are based on the completed THAOS dataset. In tafamidis-treated (n = 587) and tafamidis-untreated (n = 854) patients, respectively, median age at enrollment was 77.7 and 76.4 years, 91.8% and 90.0% were male, and 91.8% and 83.8% had wild-type disease. Survival rates (95% CI) at 30 and 42 months, respectively, were 84.4% (80.5–87.7) and 76.8% (70.9–81.7) in tafamidis-treated patients, and 70.0% (66.4-73.2) and 59.3% (55.2-63.0) in tafamidis-untreated patients. Survival rates in genotype subgroups (wild-type and variant) were similar to those of the overall cohort. Survival rates were better in a contemporary cohort, as reflected by a sensitivity analysis performed in patients enrolled after vs before 2019. No new safety signals were identified.</div></div><div><h3>Conclusions</h3><div>In this real-world cohort of patients with ATTR-CM, survival rates were higher than in ATTR-ACT and consistent with more recent reports, suggesting early diagnosis and treatment with tafamidis has improved life expectancy in ATTR-CM. These results provide further evidence supporting tafamidis’ safety and effectiveness.</div><div>Trial registration: ClinicalTrials.gov identifier: NCT00628745</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 3","pages":"Pages 525-533"},"PeriodicalIF":6.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-27DOI: 10.1016/j.cardfail.2025.02.010
Arden O'Donnell, Laura P Gelfman
{"title":"Extending the Reach: Ambulatory Specialty Palliative Care for People With Heart Failure.","authors":"Arden O'Donnell, Laura P Gelfman","doi":"10.1016/j.cardfail.2025.02.010","DOIUrl":"10.1016/j.cardfail.2025.02.010","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-27DOI: 10.1016/j.cardfail.2025.02.011
Amitai Segev, Nima Moghaddam
{"title":"Breaking Prescription Patterns: The Persistent Challenge of GDMT Underuse.","authors":"Amitai Segev, Nima Moghaddam","doi":"10.1016/j.cardfail.2025.02.011","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.02.011","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：